Home/Guides/CAR-T cost

Cost & candidacy

CAR-T Therapy Cost in 2026: China vs the United States

CAR-T is unlike anything else in this library of guides. There is no machine you travel to and no beam aimed at a tumour. CAR-T is a living drug: a patient's own T-cells are collected, genetically reprogrammed to recognise a marker on their cancer, multiplied outside the body, and returned. Each dose is manufactured for one person, and only that person.

That single fact explains almost everything about the price. A CAR-T “price” is not a hospital rate card — it is a pharmaceutical list price, attached to a product, tied to a specific approved indication. Which means the question that matters most is not what a country charges, but whether your tumour type has an approved product at all, or only a clinical trial.

China has become one of the two largest CAR-T markets in the world by approved products, trial volume and patients treated — and it is now the only country outside the United States with a broad portfolio of its own approved products. This guide sets out what is approved, what it costs in China and in the US, why patients travel, and — the part most price comparisons skip — who actually qualifies.

What CAR-T is, and why it prices differently

The process has five stages, and each one has a cost attached to it:

1. Collection (leukapheresis). A few hours on a cell-separation machine to draw the patient's T-cells.
2. Engineering. A chimeric antigen receptor (CAR) gene is inserted, so the cells can lock onto a chosen target — commonly CD19 on B-cell cancers or BCMA on myeloma.
3. Expansion. The engineered cells multiply in a specialist laboratory over roughly three to four weeks. During this window the patient often needs bridging therapy to hold the disease steady.
4. Lymphodepleting chemotherapy and infusion. A short course of chemotherapy makes room in the immune system, then the cells are infused — a single infusion, not a course of fractions.
5. Monitoring. Inpatient observation, because the two characteristic complications — cytokine release syndrome (CRS) and neurological effects (ICANS) — appear in the days after infusion and can escalate quickly.

Because each dose is a batch of one, direct manufacturing cost is high — industry estimates put it at roughly US$35,000–50,000 per dose even before research, regulatory and commercial costs are loaded on. That is why CAR-T is the one therapy in this library where a published “price” is a drug list price rather than a hospital rate card, and why the hospital bill for the surrounding care is a separate number that patients routinely underestimate.

Cost and access at a glance

Currency conversions use an indicative rate of about RMB 6.7 per US$1 (October 2026) and move with exchange rates. US figures are manufacturer list prices (WAC) for the drug product and exclude the hospital bill. Ranges are indicative, compiled from the sources listed at the end of this page — they are not quotations, and they are not a like-for-like comparison between products.

What China has approved

China's first CAR-T product was approved in June 2021. Five years later the country has nine, covering CD19-targeted lymphoma and leukaemia products and BCMA-targeted myeloma products — and, since June 2026, the world's first approved CAR-T for a solid tumour.

Two further CD19-targeted products approved in 2025–2026 bring the total to nine. Prices above are published per-infusion product prices compiled from public reporting in 2026; they are not quotations, they change, and the approved label for each product is the authority on its indications.

What it costs in China — and in the United States

In the United States, the FDA has approved seven CAR-T products. Their list prices (WAC, the manufacturer's published price before any negotiation) sit in a band of roughly US$373,000 to US$505,000 for the drug product alone, depending on the product and indication. That figure does not include leukapheresis, conditioning chemotherapy, the inpatient stay, ICU-level monitoring if CRS or ICANS is severe, or follow-up. Industry compilations commonly put those surrounding costs at a further US$100,000–300,000, and estimate an all-in total for an uninsured or international patient at US$500,000–800,000.

In China, the same class of therapy is published at roughly RMB 990,000 to RMB 1,500,000 per infusion — about US$148,000 to US$224,000 at current rates. Hospital care is charged on top of that, and the total for a course depends on how long the patient is monitored. Independent 2026 compilations of foreign-patient pricing in China place an all-in course in the region of US$110,000–206,000; other industry sources put approved-product pricing between about US$125,000 and US$215,000. The spread reflects different products, different years and very different definitions of “course”.

Two things are worth saying plainly. First, the price gap is real and large — it is the main reason patients travel. Second, the gap is not solely a China-versus-US story: within China, one product can cost 50% more than another, and the cheapest product is not automatically the right one for a given disease.

Why patients travel to China for CAR-T

The international patients who come to China for CAR-T are not choosing a country. They are responding to five specific conditions of supply, most of which have nothing to do with price.

1. Manufacturing capacity, and therefore speed. Autologous CAR-T is made one patient at a time, so the number of doses a country can deliver is limited by laboratory capacity. China expanded its cell-therapy manufacturing sector aggressively between 2020 and 2025 — industrial reporting describes domestic GMP capacity growing to the point that several product lines now have slots available without the waits some overseas centres report. For an aggressive lymphoma, where a four-week delay can matter clinically, this is often the deciding factor.
2. Trial volume and breadth. China runs more active CAR-T clinical trials than any other country — a 2024 analysis in Nature Medicine, cited widely in industry reviews, put China above 40% of all active CAR-T trials globally, and 2026 compilations count more than 500. If a patient's disease has no approved product, a trial may be the only route to CAR-T at all — and a large share of the world's solid-tumour CAR-T trials in gastric, liver, lung and pancreatic cancer are run in China.
3. Breadth of approval, including a first. Nine approved products is the widest portfolio outside the United States, and in one respect China is ahead of it: the June 2026 approval of a Claudin18.2-directed CAR-T for gastric cancer is the first regulatory approval of a CAR-T product for a solid tumour anywhere in the world. That specific option is not available elsewhere.
4. A dense network of certified centres. Industry reporting counts more than 80 Grade 3A hospitals certified by the NMPA to administer CAR-T, and cell-therapy centres have been established at 40-plus major tertiary hospitals across the country. Case volume is most concentrated in Shanghai and Beijing, but certified centres operate well beyond them.
5. Entry logistics. China operates unilateral visa-free entry for ordinary passport holders of 40-plus countries — including the UK, most of the EU, Australia, New Zealand, Japan, South Korea, Brazil and Canada — for stays of up to 30 days. That covers a first assessment trip easily. It does not necessarily cover a full treatment course, which is why the itinerary should be planned with the hospital before any travel is booked.

Who is actually eligible

CAR-T eligibility is narrower than most patients expect when they first read about it. In broad terms, it is considered for blood cancers that have relapsed or stopped responding to earlier lines of treatment.

Where the evidence and the approvals are strongest:

• Relapsed or refractory large B-cell lymphoma — the most established indication, and the first approved in China
• Follicular lymphoma and mantle cell lymphoma after prior therapy
• Adult B-cell acute lymphoblastic leukaemia
• Multiple myeloma — targeted with BCMA-directed products after multiple prior lines
• Claudin18.2-positive gastric and gastro-oesophageal junction adenocarcinoma after at least two prior lines — the newest and narrowest approved indication

What centres typically require before accepting a patient:

• Disease that has relapsed or progressed after a defined number of prior lines of therapy
• Measurable disease and a documented histology, with the relevant target marker confirmed where the label requires it
• Adequate organ function, cardiac fitness and no uncontrolled infection
• The physical reserve to tolerate lymphodepleting chemotherapy and to be monitored through possible CRS
• A caregiver, and the practical ability to remain near the treatment centre for weeks

Generally not candidates:

• Newly diagnosed blood cancers, where CAR-T is not the first-line treatment
• Most solid tumours outside a clinical trial or the one approved gastric indication
• Patients too unwell to tolerate the conditioning regimen or to survive a serious CRS episode
• Cases with contraindications set out in the specific product's approved label

Where CAR-T is delivered — and how centres are certified

Eligibility is only half the question. The other half is where, and CAR-T is unusual in how tightly that is regulated.

In China, the regulator approves the product; hospitals must then be separately qualified for each approved product. Being a large tertiary hospital is necessary but not sufficient: a centre certified for one CD19 product and indication may not be certified for a BCMA product, or for the newer solid-tumour indication. This is why the question “does this hospital do CAR-T?” is the wrong one. The right question is: is this hospital certified for the product and indication that matches my case?

Industry reporting counts more than 80 Grade 3A hospitals with such certification nationwide, and case volume is deepest in Shanghai and Beijing, with certified centres also in Guangzhou and other major cities. Crucially for international patients, certification and an international patient pathway are not the same thing. Many certified hospitals treat domestic patients extremely well and have no established machinery for a foreign patient: no medical-records translation, no visa documentation, no English-speaking coordinator, no direct billing with overseas insurers.

A smaller number of institutions have built that machinery. Among those that have publicly reported treating international CAR-T patients:

• Jiahui International Hospital, Shanghai — Shanghai's first large-scale international tertiary hospital, whose cancer centre operates in a strategic partnership with the Massachusetts General Hospital Cancer Center. It has assembled a dedicated international CAR-T team and works with manufacturers including IASO Bio and Fosun Kite. Publicly reported international cases include a New Zealand patient treated for relapsed multiple myeloma, a patient from Russia with multiple myeloma, and — in July 2026 — the first overseas patient to complete T-cell collection in China for the newly approved solid-tumour product. It is a designated CAR-T hospital under Shanghai's huhuibao supplementary scheme.
• Shanghai SinoUnited Health (曜影医疗) — a private medical group whose Shanghai hospital opened a dedicated CAR-T international consultation centre in May 2025. It is a member of the Yangtze River Delta CAR-T full-process management alliance and of the Ruijin Haematology Medical Alliance, and is one of Shanghai's first designated international medical tourism demonstration bases — offering visa support, translation and direct settlement with major international insurers. Its public reporting includes the treatment of overseas patients, including a patient from the United Kingdom in 2024.

These two are examples of institutions that have publicly reported international-patient CAR-T experience. They are not the only certified hospitals in China, this is not a ranking, and a mention here is not an endorsement of any clinical outcome. It is also worth saying that a large university-affiliated tertiary hospital in Beijing or elsewhere may hold certification for the exact product a patient needs without advertising an international service at all.

What sits outside the treatment price

Whether a patient is quoted in China or the United States, the product price is the beginning of the budget, not the end. Ask any provider to confirm in writing which of the following are included:

• Pre-treatment workup — pathology and marker testing, imaging, cardiac and organ-function assessment.
• Leukapheresis — the collection procedure itself, including the temporary central line many patients need.
• Bridging therapy during the three to four weeks of manufacturing, which can be substantial for aggressive disease.
• Lymphodepleting chemotherapy immediately before infusion.
• Inpatient monitoring — commonly one to two weeks minimum, and longer if CRS or neurological effects appear.
• ICU-level care and rescue medication if complications escalate — a major variable, and the single largest source of bill shock.
• Follow-up at roughly one, three and six months, which can usually be done at home with results sent back.
• Travel, accommodation and a companion for the full stay, which for many patients is four to ten weeks in total across two trips.
• A second product, in the minority of cases where the first fails or the disease returns.

The limits: what CAR-T is not

Price comparison pages tend to end on the upside. This one should not, because the honest picture is what makes a good decision possible.

• It is not a first-line treatment. In every approved indication, CAR-T sits after other therapies have failed — typically two or more lines. It is a later-line option, not an opening move.
• It is not available for most solid tumours. One approval exists; everything else in solid tumours is investigational and available only through trials.
• The side effects are serious. Cytokine release syndrome and neurological toxicity are common enough that treatment must take place in a centre with intensive-care capability, and they can be life-threatening.
• It is not a cure for everyone. In the pivotal trials behind these approvals, a large proportion of patients responded — but a substantial share relapse, and long-term follow-up studies show that durability correlates strongly with how long the engineered cells persist in the body. Responses at one month do not guarantee responses at three years.
• A lower price does not make it the right treatment. If a patient's disease does not match an approved indication, no price makes CAR-T appropriate outside a trial — and a good centre will say so directly.

This is why the first question we ask any CAR-T enquiry is not about budget. It is whether the diagnosis, the target marker and the prior lines of therapy line up with an approved indication — or whether the realistic path is a clinical trial, or another therapy entirely.

Frequently asked questions

How much does CAR-T cost in China?

China's approved products are published at roughly RMB 990,000 to RMB 1,500,000 per infusion (about US$148,000–224,000), depending on the product and its target. That is the drug price only — workup, leukapheresis, bridging therapy, hospitalisation with ICU-capable monitoring and follow-up are charged separately. Insist on a written, itemised quotation issued after your records have been reviewed.

Can international patients receive CAR-T in China?

Yes, at some NMPA-certified hospitals that operate an international patient pathway. China certifies hospitals for each approved CAR-T product separately, and industry reporting counts more than 80 Grade 3A hospitals holding such certification nationwide. Because certification is product- and indication-specific, and because not every certified hospital has an international service, this should be confirmed case by case before travel is planned.

Which cancers can CAR-T treat in China?

The approved indications are blood cancers: relapsed or refractory large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, adult B-cell acute lymphoblastic leukaemia, and multiple myeloma. In June 2026 China also approved the world's first CAR-T product for a solid tumour — Claudin18.2-positive gastric and gastro-oesophageal junction adenocarcinoma after at least two prior lines. All other solid-tumour use is investigational.

How long will I need to stay in China?

Most patients make two trips: one for assessment and T-cell collection, and a second, longer visit for conditioning chemotherapy, infusion and inpatient monitoring. Manufacturing commonly takes three to four weeks. Plan on roughly four to ten weeks on site in total. Note that a full course can exceed the 30-day visa-free entry available to many nationalities, so the visa should be planned deliberately rather than assumed.

Is CAR-T covered by insurance?

For international patients, usually not — assume self-pay unless your insurer confirms coverage in writing. In China, none of the approved CAR-T products is yet in the national basic medical insurance list, though several city-level supplementary schemes and commercial policies reimburse part of the cost for eligible residents. In the United States, CAR-T is covered for approved indications for insured patients, but uninsured or out-of-network international patients face list prices.

Is CAR-T better than a stem-cell transplant or a bispecific antibody?

There is no general answer. CAR-T, autologous stem-cell transplant and bispecific antibodies overlap in the same diseases and are increasingly sequenced against one another rather than chosen in isolation. Which is appropriate — and in what order — is a clinical decision for the treating team, based on the disease, prior lines of therapy and the patient's fitness. It is not a choice to be made from a price list.

Sources

• NMPA approval records, as compiled in public reporting and industry reviews (2026) — nine CAR-T products approved in China by August 2026, including the first regulatory approval worldwide of a solid-tumour CAR-T (Claudin18.2 gastric / gastro-oesophageal junction adenocarcinoma, June 2026).
• Public pricing compilations of NMPA-approved CAR-T products, 2026 (CSCO-aligned summaries and pharmaceutical trade reporting) — per-infusion product prices of approximately RMB 990,000–1,500,000, and payment status including partial coverage under city-level supplementary schemes.
• PharmaDossier, CAR-T cell therapy access landscape: seven products in 2026 — FDA-approved products, indications and manufacturer list prices (WAC); the range of approximately US$373,000–505,000 per patient for the drug product.
• CancerFax, Cost of Gene Therapy Worldwide (updated April 2026) and Top Hospitals for CAR-T Therapy in China — US list-price bands; hospital and supportive-care add-ons; NMPA certification of hospitals per product; more than 80 Grade 3A hospitals certified nationwide.
• ChinaHospitalsGuide, CAR-T Cell Therapy in China 2026 — all-in cost estimates for international patients; clinical-trial volume; the concentration of established programmes in Shanghai and Beijing.
• Nature Medicine (2024), as cited in subsequent industry reviews — China's share of active global CAR-T clinical trials (above 40%).
• Bio Conference Central, Biological Conference 2026: five trends to watch — direct manufacturing cost per dose (approximately US$35,000–50,000) and typical vein-to-vein timelines.
• Jiahui International Cancer Center, press releases and news items (2023–2026) — international CAR-T patients treated, including patients from New Zealand and Russia; strategic partnership with the Massachusetts General Hospital Cancer Center; first overseas-patient T-cell collection for the Claudin18.2 product (July 2026).
• SinoUnited Health (曜影医疗) — CAR-T international consultation centre established May 2025; membership of the Yangtze River Delta CAR-T full-process management alliance and the Ruijin Haematology Medical Alliance; Shanghai international medical tourism demonstration base.
• China News Service (Shanghai), October 2024 — international patient completing CAR-T therapy in Shanghai.
• Chinese visa policy notices, 2025–2026 — unilateral visa-free entry for ordinary passport holders of 40-plus countries, for stays of up to 30 days.

This guide is published for general information and is not medical advice, a diagnosis, or a recommendation for any particular treatment or facility. Cost figures are indicative planning ranges compiled from the sources listed above, not quotations, and they change. CAR-T therapy is appropriate only for specific indications and only a treating medical team can determine eligibility. Mention of any hospital reflects publicly reported information and is not a ranking, an endorsement, or a guarantee of any clinical outcome. OncoBridge provides information and facilitation services; it does not provide medical care and does not guarantee any clinical outcome.